Targeted Oncology Staff

During a live event, Anthony B. El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC.

During a live event, Che-Kai Tsao, MD, MS, and participants considered the tolerability and efficacy benefits of high starting doses vs dose escalation with TKIs in renal cell carcinoma.

Discover the latest breakthroughs in oncology, including FDA approvals, practice-changing trials, and insights on global cancer research disparities.

During a live event, Lori Wirth, MD, discussed preferred treatment for thyroid cancer with and without a RET, NTRK, or ALK fusion.

During a live event, Wade T. Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage small cell lung cancer.

During a live event, Cora N. Sternberg, MD, discussed tolerability outcomes from the ARANOTE trial and distinguishing aspects of androgen receptor pathway inhibitors.

During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on current data and particular challenges facing patients.

October 2025 marked a pivotal month in oncology with multiple FDA approvals and designations, enhancing treatment options for various cancers.

Discover the latest breakthroughs in oncology, including FDA designations and promising trial results that could transform cancer treatment.

During a live event, Mazyar Shadman, MD, MPH, discussed options for a patient with high-risk CLL as recommended by the NCCN guidelines.

During a live event, Che-Kai Tsao, MD, MS, and participants gave their reasoning for their choice of combination therapy for a 65-year-old patient with high-burden metastatic renal cell carcinoma.

During a live event, Hannah Choe, MD, and event participants discuss steroid-dependent chronic GVHD, favoring adding therapy over increasing steroids.

During a live event, Cora N. Sternberg, MD, discussed the development of androgen receptor pathway inhibitors and takeaways from the ARANOTE trial in hormone-sensitive prostate cancer.

During a live event, Randy F. Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma.

Discover the latest breakthroughs in oncology, including FDA approvals, clinical trial results, and innovative therapies shaping cancer treatment today.

During a live event, Anthony B. El-Khoueiry, MD, discussed downstaging for transplant and evolving frontline systemic therapies in advanced HCC.

During a live event, Wade T. Iams, MD, MSCI, examined outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer.

During a live event, Lori Wirth, MD, discussed next steps for treating a patient with progressive, radioactive iodine–refractory differentiated thyroid cancer.

During a live event, Sara Nunnery, MD, MSCI, and participants discussed impressions of recent data from the ASCENT-04 and ASCENT-03 trials.

During a live event, Nizar M. Tannir, MD and participants discussed their takeaways from trial data on recurrent RCC treatment and their personal experiences.

Discover the latest breakthroughs in oncology, including innovative treatments and FDA approvals that enhance patient care and outcomes in cancer therapy.

During a live event, Michael J. Overman, MD, discussed biomarker testing, ctDNA, and later-line treatment options for metastatic colorectal cancer.

During a live event, Martin A. Martino, MD, analyzed overall survival outcomes from the PAOLA-1, SOLO-1, and PRIMA trials.

During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic breast cancer.

During a live event, Claudine Isaacs, MD, and participants discuss using elacestrant or T-DXd after progression in ESR1-mutated metastatic breast cancer.

Discover the latest breakthroughs in oncology, including FDA approvals and promising clinical trial results that offer hope for patients battling cancer.

During a live event, Ann F. Mohrbacher, MD, discussed outcomes from the latest follow-up of the ZUMA-7 and TRANSFORM trials.

During a live event, Adriana Rossi, MD, discussed how cilta-cel induces responses and overcomes high-risk genetics in relapsed multiple myeloma.

September sees pivotal FDA approvals and designations, advancing innovative cancer treatments and reshaping oncology care for various malignancies.

During a live event, Michael C. Lowe, MD, MA, discussed how lifileucel provides an option for patients with unresectable or metastatic melanoma.